Trials / Completed
CompletedNCT00290394
Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients
Study of PPAR Gamma Agonist-Rosiglitazone in Normotensive Type 2 Diabetics With Ambulatory Blood Pressure Monitoring
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 25 (planned)
- Sponsor
- Baskent University · Academic / Other
- Sex
- All
- Age
- 49 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to determine the effects of rosiglitazone in normotensive type 2 diabetic patients with regard to its blood-pressure-reducing effects.
Detailed description
The first study to evaluate the effects of troglitazone on blood pressure in humans was published recently, which demonstrated a 5/4 mm Hg reduction in ambulatory blood pressure in 18 nondiabetic obese subjects after 12 weeks' treatment. Another study in 18 hypertensive subjects with diabetes mellitus showed an 18/12 mm Hg decline in office blood pressure after 8 weeks of treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rosiglitazone(drug), blood pressure lowering effect |
Timeline
- Start date
- 2004-03-01
- Completion
- 2004-08-01
- First posted
- 2006-02-13
- Last updated
- 2006-02-13
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00290394. Inclusion in this directory is not an endorsement.